Daniel E. Geffken

2022 - Sevion Therapeutics

In 2022, Daniel E. Geffken earned a total compensation of $64K as Interim Chief Financial Officer at Sevion Therapeutics, a 51% decrease compared to previous year.

Compensation breakdown

Other$63,960
Total$63,960

Geffken received $64K in other compensation, accounting for 100% of the total pay in 2022.

Rankings

In 2022, Daniel E. Geffken's compensation ranked 5,602nd out of 5,694 executives tracked by ExecPay. In other words, Geffken earned more than 1.6% of executives.

ClassificationRankingPercentile
All
5,602
out of 5,694
2nd
Division
Manufacturing
3,057
out of 3,099
1st
Major group
Chemicals And Allied Products
1,393
out of 1,406
1st
Industry group
Drugs
1,295
out of 1,307
1st
Industry
Biological Products, Except Diagnostic Substances
290
out of 291
0th
Source: SEC filing on April 28, 2023.

Geffken's colleagues

We found two more compensation records of executives who worked with Daniel E. Geffken at Sevion Therapeutics in 2022.

2022

Sumit Aggarwal

Sevion Therapeutics

Chief Executive Officer

2022

Vijay Modur

Sevion Therapeutics

Head of Research and Development

News

You may also like